NICE recommends first immunotherapy for limited-stage small cell lung cancer

The National Institute for Health and Care Excellence (NICE) has recommended the first immunotherapy for limited-stage small cell lung cancer (LS-SCLC) for use on the NHS in England and Wales. In final draft guidance, published on 16 September 2025, NICE approved durvalumab (Imfinzi; AstraZeneca) for adults whose cancer has not progressed after platinum-based chemoradiotherapy. The […]

Publication Details

Journal: Pharmaceutical journal/The pharmaceutical journal
Published: 2025-01-01
DOI: https://doi.org/10.1211/pj.2025.1.373887
Primary Topic: Lung Cancer Research Studies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

NICE recommends first immunotherapy for limited-stage small cell lung cancer

Jan 1, 2025

Pharmaceutical journal/The pharmaceutical journal

Lung Cancer Research Studies

article

NICE recommends first immunotherapy for limited-stage small cell lung cancer

January 1, 2025article en

Abstract

Pharmaceutical journal/The pharmaceutical journal

Openalex Percentile: Top 66%

Lung Cancer Research Studies

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

NICE recommends first immunotherapy for limited-stage small cell lung cancer · Pharmaceutical journal/The pharmaceutical journal (2025) | TGRS Research Map | TGRS